Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chirag Shah

Pulmonary Disease Land O Lakes, FL Doctor of Osteopathy

NPI 1790863314 CMS profile 127043

2100 Via Bella Blvd, Suite 102, Land O Lakes, FL 34639

Open in the dashboard

General payments

$23,081

1,189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chirag Shah of Land O Lakes, FL is reported in the CMS Open Payments database as having received $23,081 across 1,189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,858 172
2024 General $3,409 164
2023 General $3,578 160
2022 General $3,107 151
2021 General $3,155 167
2020 General $2,788 182
2019 General $3,185 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chirag Shah
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Chirag Shah were reported at $3,858. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Chirag Shah Pulmonary Disease median Middle half National median
2019 $3,185 $377 $109–$1,340 $163
2020 $2,788 $230 $56–$907 $114
2021 $3,155 $269 $68–$1,072 $132
2022 $3,107 $390 $100–$1,457 $149
2023 $3,578 $419 $114–$1,659 $160
2024 $3,409 $476 $123–$1,818 $164
2025 $3,858 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $5,329 315 payments
  2. AstraZeneca Pharmaceuticals LP $4,139 203 payments
  3. Jazz Pharmaceuticals Inc. $1,516 66 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,229 66 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,172 56 payments
  6. Actelion Pharmaceuticals US, Inc. $885 37 payments
  7. Amgen Inc. $855 42 payments
  8. Insmed, Inc. $653 39 payments
  9. Philips Electronics North America Corporation $645 46 payments
  10. United Therapeutics Corporation $618 31 payments
  11. Other $6,041 288 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,015 1,163 payments
  2. Education $1,065 26 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $3,214 183 payments
  2. FASENRA $1,699 72 payments
  3. NUCALA $1,212 64 payments
  4. GLASSIA $1,180 56 payments
  5. XYWAV $1,017 41 payments
  6. BREZTRI $910 38 payments
  7. SPIRIVA RESPIMAT $825 45 payments
  8. OPSUMIT $824 35 payments
  9. TEZSPIRE $794 39 payments
  10. UPTRAVI $676 28 payments
  11. Other $13,701 681 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

3,990

Median for Pulmonary Disease: 936

Drug cost

$2,475,461

Median for Pulmonary Disease: $487,987

Branded share of claims

65.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 526 $546,085
Ofev Nintedanib Esylate Brand 31 $407,465
Tyvaso Dpi Treprostinil Brand 12 $268,740
Opsumit Macitentan Brand 14 $176,383
Spiriva Respimat Tiotropium Bromide Brand 148 $136,366
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 127 $132,058
Esbriet Pirfenidone Brand 12 $125,668
Glassia Alpha-1-Proteinase Inhibitor Brand 13 $115,832
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 133 $115,208
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 131 $112,102

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$207,008

Medicare's payments for the services billed

Medicare patients

806

Average age 75

Services billed

3,020

431 women, 375 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 50%
COPD 46%
Diabetes 42%
Chronic kidney disease 42%
Depression 34%
Heart failure 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$460 526 —
TEZSPIRE
$368 — —
GLASSIA
$281 13 —
NUCALA
$260 — —
FASENRA
$248 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record